The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Targeting replication stress in pancreatic cancer: A phase II trial investigating azenosertib in combination with gemcitabine in second-line advanced pancreatic cancer.
 
Brandon Huffman
Consulting or Advisory Role - Loxo/Lilly
 
Nora K. Horick
Employment - Northwest Biotherapeutics (I)
Stock and Other Ownership Interests - Northwest Biotherapeutics (I)
Patents, Royalties, Other Intellectual Property - An immediate family member holds patents, has patents pending, and receives royalties from a technology relating to health or medicine. (I)
 
Alexandra Bird
No Relationships to Disclose
 
Caroline Gibson
No Relationships to Disclose
 
Lauren K. Brais
No Relationships to Disclose
 
Christopher Graham
No Relationships to Disclose
 
Benjamin L. Schlechter
Consulting or Advisory Role - Agenus; Janssen; Quercegen Pharmaceuticals
 
Brian M. Wolpin
Consulting or Advisory Role - Agenus; EcoR1 Capital; GRAIL; Ipsen; Mirati Therapeutics; Revolution Medicines; Third Rock Ventures
Research Funding - AstraZeneca (Inst); Harbinger Health (Inst); Lilly (Inst); Novartis (Inst); Revolution Medicines (Inst)
 
Andrew Aguirre
Stock and Other Ownership Interests - Kestrel Therapeutics; Riva Therapeutics
Honoraria - Phillips Gilmore Oncology
Consulting or Advisory Role - Alcon (I); Arrakis Therapeutics; AstraZeneca; Boehringer Ingelheim; Merck; Mirati Therapeutics; Nimbus Therapeutics; Plexium; Revolution Medicines; Riva Therapeutics; SERVIER; Syros Pharmaceuticals; T-Knife; Third Rock Ventures
Research Funding - Bristol-Myers Squibb/Celgene; Deerfield Management; Mirati Therapeutics; Novartis; Novo Ventures; Revolution Medicines; Syros Pharmaceuticals
 
Alan D. D'Andrea
Stock and Other Ownership Interests - Cyteir; IMPAC Medical Systems; PrimeFour Therapeutics
Consulting or Advisory Role - Blacksmith/Lightstone Ventures; Bristol Myers Squibb; Covant Therapeutics/Roivant; cyteir; Deerfield Management Company; Faze Medicines; IMPAC Medical Systems; Pfizer; PrimeFour Therapeutics; Servier Bio-Innovation LLC; Tango Therapeutics; Zentalis Pharmaceuticals/Zeno Management
Research Funding - Bristol Myers Squibb; Merck Serono; Moderna Therapeutics; Tango Therapeutics
Travel, Accommodations, Expenses - IDEAYA Biosciences
 
Geoffrey Ira Shapiro
Consulting or Advisory Role - Bicycle Therapeutics; Merck Serono; Xinthera
Research Funding - Bristol-Myers Squibb/Medarex (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Pfizer (Inst); Tango Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent # 10,934,593 B2 Compositions and methods for predicting response and resistance to CDK4/6 inhibition; Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018
 
James M. Cleary
Honoraria - Blueprint Medicines; Incyte; Syros Pharmaceuticals
Research Funding - Apexigen; Arcus Biosciences; Arcus Biosciences; AstraZeneca; Bayer; BMS (Inst); BMS (Inst); Esperas Pharma; Merck; Merus (Inst); Roche/Genentech (Inst); SERVIER (Inst); Tesaro
Travel, Accommodations, Expenses - Agios; Bristol-Myers Squibb; Incyte; Roche